KalVista Pharmaceuticals (NASDAQ:KALV) Hits New 52-Week High – Should You Buy?

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $26.75 and last traded at $26.7350, with a volume of 32743624 shares trading hands. The stock had previously closed at $19.24.

Trending Headlines about KalVista Pharmaceuticals

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Chiesi Group agreed to acquire KalVista for about $1.9 billion and to buy shares for $27.00 in cash — the deal highlights Chiesi’s push into rare-disease/HAE treatment Ekterly and is the primary catalyst for the stock’s jump. Chiesi to buy KalVista in $1.9B deal
• Positive Sentiment: Market reaction: shares surged roughly 38–39% on the takeover news and trading volume spiked well above average, reflecting investor demand to capture the cash takeover consideration. KalVista stock surges 39%
• Neutral Sentiment: Trading mechanics: trading in KALV was temporarily halted prior to the announcement for “news pending,” a routine step that precedes major corporate news and can amplify post-release moves. (Company/regulatory filings reflected the halt.)
• Neutral Sentiment: Analyst view: Needham & Company reaffirmed a “hold” rating on KalVista — a reminder some analysts view the takeover price as fair or limited upside beyond the offer. Needham reaffirms hold
• Negative Sentiment: Litigation risk: multiple shareholder-alerts and law-firm investigations (Ademi LLP and Monteverde & Associates) have been announced questioning whether the $27.00 per-share deal is fair and whether fiduciary duties were met — these actions could delay closing, prompt a negotiated price change, or produce settlement costs. Ademi LLP shareholder alert Monteverde investigation

Analyst Ratings Changes

Several brokerages recently issued reports on KALV. HC Wainwright upped their price objective on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research note on Friday, January 9th. Leerink Partners cut shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. Wall Street Zen cut shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 21st. Citizens Jmp cut shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. Finally, JonesTrading cut shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday. Four equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $32.60.

KalVista Pharmaceuticals Stock Down 0.0%

The company has a current ratio of 7.22, a quick ratio of 7.21 and a debt-to-equity ratio of 8.18. The company has a market capitalization of $1.37 billion, a price-to-earnings ratio of -6.75 and a beta of -0.40. The firm’s fifty day simple moving average is $18.45 and its two-hundred day simple moving average is $15.72.

Insider Transactions at KalVista Pharmaceuticals

In other news, CEO Benjamin L. Palleiko sold 10,034 shares of the company’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $15.57, for a total value of $156,229.38. Following the transaction, the chief executive officer directly owned 442,883 shares in the company, valued at approximately $6,895,688.31. This represents a 2.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Paul K. Audhya sold 5,354 shares of the company’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total transaction of $83,361.78. Following the completion of the transaction, the insider owned 138,983 shares in the company, valued at approximately $2,163,965.31. This represents a 3.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 263,969 shares of company stock worth $4,536,178. 4.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Large investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets lifted its holdings in shares of KalVista Pharmaceuticals by 47.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after acquiring an additional 1,292 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of KalVista Pharmaceuticals in the 3rd quarter worth approximately $55,000. Wolverine Asset Management LLC acquired a new position in shares of KalVista Pharmaceuticals in the 3rd quarter worth approximately $57,000. KLP Kapitalforvaltning AS purchased a new stake in KalVista Pharmaceuticals during the 3rd quarter worth approximately $63,000. Finally, Truvestments Capital LLC increased its stake in KalVista Pharmaceuticals by 253.8% during the 4th quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock worth $76,000 after buying an additional 3,360 shares during the period.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.